Proactiveinvestors United Kingdom MaxCyte https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom MaxCyte RSS feed en Mon, 22 Apr 2019 13:41:22 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - MaxCyte launches latest iteration of its Flow Electroporation cell editing technology ]]> https://www.proactiveinvestors.co.uk/companies/news/218113/maxcyte-launches-latest-iteration-of-its-flow-electroporation-cell-editing-technology-218113.html MaxCyte Inc (LON:MXCT) has launched an updated version of its Flow Electroporation cellular editing technology.

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

LOOK: Take a look at ExPERT’s new features

This latest generation of tools, called ExPERT, boasts new updated software, a touchscreen interface and other features that MaxCyte says represent a “significant improvement” to the user experience.

The combination of the new instruments, together with the launch of a new range of processing assemblies, will allow customers to use a single technology from early research through to clinical and commercial use.

“We are proud to announce the launch of our next-generation ExPERT brand of instruments,” said chief executive and president Doug Doerfler.

Executive vice president of global commercial operations, Brad Calvin, added: “The ExPERT instrument family is the result of extensive customer research into feature design, functionality and performance that are considered critical to enabling the next generation of cellular therapies.

“Creating cellular editing platforms standardized on a single, scalable, high performance technology can assist the industry in accelerating timelines, reducing costs and achieving milestones critical to the translation of this promising new generation of cellular therapies.”

]]>
Mon, 08 Apr 2019 07:26:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218113/maxcyte-launches-latest-iteration-of-its-flow-electroporation-cell-editing-technology-218113.html
<![CDATA[RNS press release - Launch of ExPERTT Instrument Family ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190408070007_14031646/ Mon, 08 Apr 2019 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190408070007_14031646/ <![CDATA[RNS press release - Notice of Full Year Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190326070022_14015201/ Tue, 26 Mar 2019 07:00:22 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190326070022_14015201/ <![CDATA[RNS press release - Director Dealings ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190319170523_14008049/ Tue, 19 Mar 2019 17:05:23 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190319170523_14008049/ <![CDATA[RNS press release - Grant of Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190305070010_13989807/ Tue, 05 Mar 2019 07:00:10 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190305070010_13989807/ <![CDATA[News - MaxCyte extends relationship with Gilead Sciences-owned cancer drug developer Kite ]]> https://www.proactiveinvestors.co.uk/companies/news/215587/maxcyte-extends-relationship-with-gilead-sciences-owned-cancer-drug-developer-kite-215587.html Life sciences group MaxCyte Inc (LON:MXCT) has extended its relationship with Kite – the multi-billion-dollar cancer drug developer owned by US giant Gilead Sciences.

Under the terms of this latest agreement, Kite will use MaxCyte’s Flow Electroporation technology to help it develop “multiple” CAR-T drug candidates for up to ten targets.

READ: MaxCyte inks research agreement with Gilead subsidiary Kite Pharma

“We're excited to take our relationship with Kite further into product development, providing the company with the ability to leverage MaxCyte's versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics,” said MaxCyte president and chief executive Doug Doerfler.

In CAR-T, patient immune cells are extracted, genetically modified with a receptor to target certain cancer cells, then reinfused back into the patient.

This is where MaxCyte’s technology comes in: it allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

In return for granting Kite the non-exclusive rights to use its cell engineering platform, Maryland, US-based MaxCyte will receive development and approval milestones and sales-based payments, as well as other licensing fees.

The expansion of the Kite-MaxCyte relationship builds on an existing research agreement announced in November 2018.

]]>
Fri, 01 Mar 2019 07:31:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215587/maxcyte-extends-relationship-with-gilead-sciences-owned-cancer-drug-developer-kite-215587.html
<![CDATA[RNS press release - Clinical & Commercial Agreement with Kite ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190301070007_13986360/ Fri, 01 Mar 2019 07:00:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190301070007_13986360/ <![CDATA[RNS press release - Result of Special Meeting and Issue of Equity ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190226173236_13982612/ Tue, 26 Feb 2019 17:32:36 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190226173236_13982612/ <![CDATA[Media files - MaxCyte raises £10mln to extend its CARMA platform into a second trial ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/12198/maxcyte-raises-10mln-to-extend-its-carma-platform-into-a-second-trial-12198.html Tue, 12 Feb 2019 20:09:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/12198/maxcyte-raises-10mln-to-extend-its-carma-platform-into-a-second-trial-12198.html <![CDATA[News - Maxcyte fighting cancer battle on two fronts via experimental targeted treatment and technology licensing deals ]]> https://www.proactiveinvestors.co.uk/companies/news/214111/maxcyte-fighting-cancer-battle-on-two-fronts-via-experimental-targeted-treatment-and-technology-licensing-deals-214111.html MaxCyte Inc (LON:MXCT) is developing an experimental targeted cancer treatment but also licenses out the technology to larger biotechs and pharma companies, including the international giant Gilead Sciences Inc (NASDAQ:GILD), to aid their discovery process.

It is involved with 70 programmes, of which half are at the clinical stage of development.

MaxCyte’s CARMA platform is being used to develop some of the first drug candidates that use the company’s own immune system to fight solid tumours.

Its lead candidate, MCY-M11 is what’s known as a chimeric antigen receptor, CAR therapy, which gives T-cells the new ability to target a specific protein.

T-cells are part of the immune system and circulate around our bodies, scanning for cellular abnormalities and infections.

MCY-M11 is a mesothelin targeting CAR that will be used to treat ovarian cancer and peritoneal mesothelioma, which forms around the tissue lining of the womb.

How is it doing:

In October 2018, MaxCyte saw the first patient dosed in an initial phase I trial using MCY-M11. A total of 15 women with relapsed or hard-to-treat forms of the disease will receive the drug, which is being assessed primarily for safety and whether it is well tolerated by those taking it.

In November 2018, MaxCyte announced a trio of commercial license deals for its Flow Electroporation Technology (FET) with US firms.

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

Under a research agreement, Maxcyte said Kite Pharma Inc - a subsidiary of US drugmaker Gilead - would use its FET platform to enable non-viral cell engineering.

Meanwhile, a clinical and commercial licence deal with Precision Biosciences will see it use MaxCyte's FET technology alongside its own ARCUS genome-editing platform.

That tie-up built on a research and clinical licence agreement the two already had. Under the new terms, MaxCyte will receive undisclosed milestone payments and technology access licensing fees.

Maxcyte’s Flow Electroporation technology will also be used by CRISPR Therapeutics as part of its quest to develop new gene therapies for the treatment of cancer.

In this case, under a commercial license deal, CRISPR will use the technology to deliver its components into T-cells which attack the body’s own cells that have been invaded by viruses or bacteria.

To help with the acceleration of its growth strategy, as well as executing “significant commercial opportunities”, this week, Maxcyte raised £10mln via a share placing.

The cell-based medicines developer said around 5.8mln new shares were placed at a price of 170p each, an 8% discount to its closing price of 185p on the day before the placing.

The group said the funds would also be used to help expand the core customer base and instrument business, including new product development and applications in large-scale biopharmaceutical transient protein manufacturing, in addition to advancing the company’s CARMA pipeline for the treatment of solid tumours, more specifically an intravenous administration programme.

What the boss says - Doug Doerfler:

"Since listing on AIM in 2016, we have continued to make significant progress across all areas of the business, supporting our biopharmaceutical partners in developing new classes of medicines for patients with inherited genetic diseases, infectious diseases and cancer.”

“We've also made important progress with our high-value CARMA immuno-oncology platform, advancing MCY-M11, our wholly-owned lead therapeutic candidate, into the clinic in 2018 in our US-based Phase I clinical trial and validating our innovative one-day manufacturing process.”

Inflection points:

In January, Maxcyte said its 2018 underlying earnings (EBITDA) are likely to show “an improvement on market expectations” after a bumper end to the year.

The group pointed out that revenues increased 19% year-on-year to US$16.7mln in the 12 months to December 31, with top-line growth of 25% in the second six months.

Combined potential milestone payments for deals signed are US$250mln, the company also said in its trading update.

Looking ahead, the company said expects it to maintain the momentum in 2019.

Blue Sky:

From 28 November 2018, Maxcyte simplified it’s share structure, with all common stock to be held as unrestricted shares after merging its two separate classes of unrestricted and Regulation S restricted equity.

The move was intended to help both trading liquidity and transparency for shareholders.

Although Maxcyte shares dipped after the February share placing, at 180p each the group is currently valued at £92.40mln, well below the 300p-plus level reached in April 2017.

]]>
Wed, 06 Feb 2019 15:40:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214111/maxcyte-fighting-cancer-battle-on-two-fronts-via-experimental-targeted-treatment-and-technology-licensing-deals-214111.html
<![CDATA[RNS press release - Results of Placing ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190205163243_13959287/ Tue, 05 Feb 2019 16:32:43 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190205163243_13959287/ <![CDATA[News - MaxCyte raises £10mln in share placing to accelerate growth strategy ]]> https://www.proactiveinvestors.co.uk/companies/news/213955/maxcyte-raises-10mln-in-share-placing-to-accelerate-growth-strategy-213955.html MaxCyte Inc (LON:MXCT) has raised £10mln in a share placing to fund an acceleration of its growth strategy as well as executing “significant commercial opportunities”.

The cell-based medicines developer said it raised the fund through the placing of around 5.8mln new shares at a price of 170p each, an 8% discount to its last close price of 185p.

WATCH: MaxCyte raises £10mln to extend its CARMA platform into a second trial

MaxCyte said the proceeds of the placing would be used to fund the expansion of its cell therapy pipeline as well as accelerating “high-value clinical and commercial deals” in fields such as immune-oncology, gene editing, and regenerative medicine.

The funds would also be used to help expand the core customer base and instrument business, including new product development and applications in large-scale biopharmaceutical transient protein manufacturing, in addition to advancing the company’s CARMA pipeline for the treatment of solid tumours, more specifically an intravenous administration programme.

MaxCyte also said it had placed 320,223 shares to unconnected shareholders at the same time as the placing and at the placing price as well as 50,417 shares pursuant to the cashless exercise of options by certain unconnected stockholders.

READ: MaxCyte says earnings likely to beat expectations after bumper end to the year

Doug Doerfler, president and chief executive of MaxCyte, said: "Since listing on AIM in 2016, we have continued to make significant progress across all areas of the business, supporting our biopharmaceutical partners in developing new classes of medicines for patients with inherited genetic diseases, infectious diseases and cancer.”

“We've also made important progress with our high-value CARMA immuno-oncology platform, advancing MCY-M11, our wholly-owned lead therapeutic candidate, into the clinic in 2018 in our US-based Phase I clinical trial and validating our innovative one-day manufacturing process” he added.

At close on Tuesday, MaxCyte shares were at 180p.

--Adds result of placing and updates share price--

]]>
Tue, 05 Feb 2019 07:43:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/213955/maxcyte-raises-10mln-in-share-placing-to-accelerate-growth-strategy-213955.html
<![CDATA[RNS press release - Proposed Placing to raise a minimum of £10 million ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190205070007_13957922/ Tue, 05 Feb 2019 07:00:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190205070007_13957922/ <![CDATA[News - MaxCyte says earnings likely to beat expectations after bumper end to the year ]]> https://www.proactiveinvestors.co.uk/companies/news/212562/maxcyte-says-earnings-likely-to-beat-expectations-after-bumper-end-to-the-year-212562.html MaxCyte Inc (LON:MXCT) has said its underlying earnings (EBITDA) are likely to show “an improvement on market expectations” after a bumper end to the year.

Revenues increased 19% year-on-year to US$16.7mln in the 12 months to December 31, with top-line growth of 25% in the second six months. Looking ahead, the company said expects it to maintain the momentum in 2019.

MaxCyte is developing a new cancer treatment, but also licenses out the technology to larger biotechs and pharma companies, including the international giant Gilead, to aid their discovery process.

It is involved with 70 programmes, of which half are at the clinical stage of development.

Combined potential milestone payments for deals signed are US$250mln, the company said in its trading update.

CARMA 

MaxCyte’s CARMA platform is being used to develop some of the first drug candidates that use the company’s own immune system to fight solid tumours.

Currently, the batches of drugs in development have focused on blood-borne disease.

Its lead chimeric antigen receptor therapeutic candidate, MCY-M11, entered phase I clinical trials in October.

It is being used to treat people women with relapsed, or refractory (hard to treat) ovarian cancer and peritoneal mesothelioma, which affects the lining of the abdomen.

“This continues to be a very exciting time for the company and patients as we bring a new generation of CAR-based solid cancer treatments into the clinic for the first time. We look forward to the future with great confidence," said chief executive Doug Doerfler.

]]>
Tue, 15 Jan 2019 07:36:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212562/maxcyte-says-earnings-likely-to-beat-expectations-after-bumper-end-to-the-year-212562.html
<![CDATA[RNS press release - Trading Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190115070005_13934357/ Tue, 15 Jan 2019 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20190115070005_13934357/ <![CDATA[RNS press release - Change of Auditor ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181219070004_13908852/ Wed, 19 Dec 2018 07:00:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181219070004_13908852/ <![CDATA[RNS press release - Director Dealings ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181217180651_13906896/ Mon, 17 Dec 2018 18:06:51 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181217180651_13906896/ <![CDATA[News - MaxCyte updates on plans to simplify share structure ]]> https://www.proactiveinvestors.co.uk/companies/news/209647/maxcyte-updates-on-plans-to-simplify-share-structure-209647.html MaxCyte (LON:MXCT) said from November 28 all common stock will be held as unrestricted shares as it provided an update on plans to merge two separate classes of equity.

The move is intended to help both trading liquidity and transparency for shareholders.

MaxCyte currently has two classes of shares: unrestricted and Regulation S restricted. For more information click here.

]]>
Wed, 21 Nov 2018 07:38:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/209647/maxcyte-updates-on-plans-to-simplify-share-structure-209647.html
<![CDATA[RNS press release - Consolidation of Trading Lines ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181121070005_13874320/ Wed, 21 Nov 2018 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181121070005_13874320/ <![CDATA[RNS press release - Block Admission Six Monthly Return/TVR ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181120070017_13872738/ Tue, 20 Nov 2018 07:00:17 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181120070017_13872738/ <![CDATA[RNS press release - Webinar: non-viral cell engineering ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181116070004_13869325/ Fri, 16 Nov 2018 07:00:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181116070004_13869325/ <![CDATA[News - MaxCyte teams up with American gene editing specialist to develop new generation of cancer treatments ]]> https://www.proactiveinvestors.co.uk/companies/news/209151/maxcyte-teams-up-with-american-gene-editing-specialist-to-develop-new-generation-of-cancer-treatments-209151.html MaxCyte PLC (LON:MXCT) has negotiated a clinical and commercial licence deal with Precision Biosciences of the US.

Under the terms of the agreement, Precision will use MaxCyte's flow electroporation cell engineering technology alongside its own ARCUS genome-editing platform.  

The plan is to develop the next generation of cell-based therapies for cancer.

READ: MaxCyte inks research agreement with Gilead subsidiary Kite Pharma​

"Precision's therapeutic grade ARCUS editing platform is sufficiently compact and specific to use with a range of delivery systems,” said its chief development officer David Thomson.

“In considering these, we have found MaxCyte's electroporation technology complements our approach to allogeneic T cell manufacturing, which is focused on preserving cell quality throughout the process while maximising overall yield."

Building on earlier deal 

The new tie-up builds on a research and clinical licence agreement the two already had. Under the new terms, MaxCyte will receive undisclosed milestone payments and technology access licensing fees.

"The initiation of this commercial license agreement with Precision, a leader in genome editing with its own proprietary ARCUS technology, signifies a key milestone for MaxCyte and demonstrates the value and versatility of our platform, our intellectual property, and our ability to foster important collaborations with companies generating life-changing gene therapies," said MaxCyte chief executive Doug Doerfler.

The AIM-listed life sciences group’s flow electroporation technology allows cells to be re-engineered efficiently, with high viability and recovery.

Precision will use its ARCUS gene editing tools and the MaxCyte’s breakthrough to transform donor cells into immunotherapies such CAR-T cells.

]]>
Wed, 14 Nov 2018 07:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/209151/maxcyte-teams-up-with-american-gene-editing-specialist-to-develop-new-generation-of-cancer-treatments-209151.html
<![CDATA[RNS press release - Clinical and Commercial License Agreement ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181114070003_13865858/ Wed, 14 Nov 2018 07:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181114070003_13865858/ <![CDATA[Media files - Major announcements for MaxCyte ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11185/major-announcements-for-maxcyte-11185.html Tue, 13 Nov 2018 11:38:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11185/major-announcements-for-maxcyte-11185.html <![CDATA[News - MaxCyte inks research agreement with Gilead subsidiary Kite Pharma ]]> https://www.proactiveinvestors.co.uk/companies/news/208981/maxcyte-inks-research-agreement-with-gilead-subsidiary-kite-pharma-208981.html MaxCyte Inc (LON:MXCT) has signed a research agreement with Kite Pharma Inc, a subsidiary of US drugmaker Gilead Sciences Inc (NASDAQ:GILD), to use its Flow Electroporation Technology (FET) platform.

The AIM-listed bioscience firm said under the agreement Kite would use the FET platform to enable non-viral cell engineering.

WATCH: Major announcements for MaxCyte

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

Doug Doerfler, president and chief executive of MaxCyte, said Kite would be utilising the firm’s platform to enable gene-editing technologies for the research and development of new therapeutics.

The deal follows a commercial license agreement signed last week between MaxCyte and gene-based medicine maker CRISPR Therapeutics in a move to advance the development of anti-cancer treatments.

]]>
Mon, 12 Nov 2018 07:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208981/maxcyte-inks-research-agreement-with-gilead-subsidiary-kite-pharma-208981.html
<![CDATA[RNS press release - MaxCyte Announces Research Agreement with Kite ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181112070005_13862552/ Mon, 12 Nov 2018 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181112070005_13862552/ <![CDATA[News - CRISPR Therapeutics to use MaxCyte’s technology in its search for cancer gene therapies ]]> https://www.proactiveinvestors.co.uk/companies/news/208897/crispr-therapeutics-to-use-maxcytes-technology-in-its-search-for-cancer-gene-therapies-208897.html MaxCyte Inc’s (LON:MXCT) Flow Electroporation technology will be used by CRISPR Therapeutics as part of its quest to develop new gene therapies for the treatment of cancer after the pair signed a commercial licence agreement.

Doug Doerfler, MaxCyte chief executive, said the agreement was a “validation” of his firm’s technology, while CRISPR boss, Samarth Kulkarni, said he was pleased to have secured access to “the leading ex vivo delivery platform for both clinical and commercial use”.

READ: MaxCyte on track to start first-ever clinical trial before year-end

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

In this case, CRISPR will use the technology to deliver its components into T-cells which attack the body’s own cells that have been invaded by viruses or bacteria.

Today’s (Friday’s) tie-up expands the relationship between MaxCyte and CRISPR. The two signed a deal last year which allowed the latter to use Flow Electroporation as part of its efforts to develop treatments for haemoglobin-related diseases.

In return for supplying its technology, MaxCyte will receive milestone and sales-based payments in addition to other licensing fees.

“The expansion of our relationship with CRISPR Therapeutics signifies a key milestone for MaxCyte and our technology, providing further validation for the value and versatility of our technology as a leading enabler of next-generation cell-based therapies," said MaxCyte President and CEO Doug Doerfler.

“CRISPR Therapeutics is a leader in gene editing, and we are very pleased to expand our collaboration into new therapeutic areas as we continue to explore the use of our technology to advance medicines to market that will make a difference for patients.”

]]>
Fri, 09 Nov 2018 07:41:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208897/crispr-therapeutics-to-use-maxcytes-technology-in-its-search-for-cancer-gene-therapies-208897.html
<![CDATA[RNS press release - Expansion of CRISPR Commercial License Agreement ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181109070002_13860960/ Fri, 09 Nov 2018 07:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181109070002_13860960/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181031162509_13850111/ Wed, 31 Oct 2018 16:25:09 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181031162509_13850111/ <![CDATA[Media files - MaxCyte doses first ovarian cancer patient in phase 1 clinical trial ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10889/maxcyte-doses-first-ovarian-cancer-patient-in-phase-1-clinical-trial-10889.html Wed, 17 Oct 2018 13:52:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10889/maxcyte-doses-first-ovarian-cancer-patient-in-phase-1-clinical-trial-10889.html <![CDATA[News - MaxCyte doses first phase I patient ]]> https://www.proactiveinvestors.co.uk/companies/news/206749/maxcyte-doses-first-phase-i-patient-206749.html MaxCyte PLC (LON:MXCT) said the first patient had been dosed with its experimental targeted treatment for cancer.

MCY-M11 is what’s known as a chimeric antigen receptor, or CAR therapy, which gives T-cells the new ability to target a specific protein.

T-cells are part of the immune system and circulate around our bodies, scanning for cellular abnormalities and infections.

Ovarian cancer targeted 

MCY-M11 is a mesothelin targeting CAR that will be used to treat ovarian cancer and peritoneal mesothelioma, which forms around the tissue lining of the womb.

A total of 15 women with relapsed or hard-to-treat forms of the disease will receive the drug, which is being assessed primarily for safety and whether it is well tolerated by those taking it.

"The initiation of patient dosing in our first clinical trial with our lead CAR therapeutic candidate is a significant milestone for MaxCyte, validating our streamlined manufacturing process for clinical use," said MaxCyte chief executive Doug Doerfler.

"We are extremely pleased to have very experienced investigators at two leading clinical centres conducting this study in solid tumours.

“We believe this clinical trial will further demonstrate the potential of our proprietary CARMA (CAR therapeutic) autologous cell-therapy platform to develop meaningful, targeted cell-based immune therapies."

 

]]>
Wed, 10 Oct 2018 07:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/206749/maxcyte-doses-first-phase-i-patient-206749.html
<![CDATA[RNS press release - Dosing Begins in First Clinical Trial of MCY-M11 ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181010070005_13822545/ Wed, 10 Oct 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181010070005_13822545/ <![CDATA[RNS press release - Notice of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181008070006_13819274/ Mon, 08 Oct 2018 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20181008070006_13819274/ <![CDATA[News - MaxCyte on track to start first-ever clinical trial before the end of the year ]]> https://www.proactiveinvestors.co.uk/companies/news/205512/maxcyte-on-track-to-start-first-ever-clinical-trial-before-the-end-of-the-year-205512.html MaxCyte Inc (LON:MXCT) expects to dose the first patients in its first-ever clinical trial before the end of this year.

Over summer, the US Food and Drug Administration gave the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours.

READ: All you need to know about CAR-T therapies

The phase I clinical study will evaluate the safety of the potential treatment in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma (a form of cancer that affects the abdomen).

MaxCyte used its CARMA platform to develop the cancer treatment. The technology incites the body’s own immune system to tackle the killer disease, which is a hot area at the moment.

New and innovative tech

What’s new and innovative, even for this very new and innovative strand of research, is that CARMA is being designed to grapple with solid tumours.

The breakthroughs in this field, such as CAR (chimeric antigen receptor) T-cell immuno-therapies, fight blood-borne illness, and yet 90% of cancers are solid tumours.

Chief executive Doug Doerfler repeated his statement that the regulatory sign-off marked an “important milestone” for MaxCyte.

“We hope that the results of this upcoming phase I study, which we plan to start before year-end, will serve as validation of our proprietary CARMA drug platform as a whole,” read Monday’s half-year report.

MaxCyte isn’t the typical, binary, heads-you-win, tails-you-lose drug developer you find traditionally on AIM.

It has a hybrid business. So, it sells and licenses its cell engineering technology to some of the world’s largest pharma and biotechnology companies.

Revenues rise

As flagged in July’s trading update, revenue climbed 11.6% to US$6.9mln in the six months ended June 30 (H1 17: US$6.2mln), in line with what the market had been expecting.

It is partnered with commercial and academic cell therapy developers and revealed it now has more than 55 licenced programmes covering an increasingly diverse range of fields, including immuno-oncology, gene editing and regenerative medicine.

MaxCyte also increased the number of licences to partners covering clinical-stage programmes to more than 25 (up from 15 at the same point last year).

“We are in an excellent position across the business as MaxCyte continues to grow and gain momentum,” added Doerfler.

“This is a very exciting and important time for the company, our partners and patients as we bring a new generation of CAR-based cancer treatments into the clinic for the first time and support the increasing number of clinical and commercial advancements of our partners' therapeutics.”

Overall, the company turned a net loss of US$2.2mln (H1 17: US$2.2mln), while cash stood at US$18.8mln (H1 17: US$25.3mln) at the end of the period.

Shares were unchanged at 234p on Monday morning.

]]>
Mon, 24 Sep 2018 08:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205512/maxcyte-on-track-to-start-first-ever-clinical-trial-before-the-end-of-the-year-205512.html
<![CDATA[RNS press release - Results for the Half Year ended 30 June 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180924070010_13801047/ Mon, 24 Sep 2018 07:00:10 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180924070010_13801047/ <![CDATA[RNS press release - Grant of Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180910070007_13783864/ Mon, 10 Sep 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180910070007_13783864/ <![CDATA[News - CAR-T therapies: All you wanted to know and were too afraid to ask ]]> https://www.proactiveinvestors.co.uk/companies/news/204261/car-t-therapies-all-you-wanted-to-know-and-were-too-afraid-to-ask-204261.html A new cutting-edge cancer treatment has been given the green light by the UK authorities after a deal over pricing was reached with its developer Novartis AG (SWX:NOVN).

Kymriah will be available for children and young people with aggressive leukaemia and is one of a new generation of treatments that uses the body’s own immune system to tackle the killer disease.

It what’s called a CART-T therapy, which stands for chimeric antigen receptor T-cell. As the name suggests the technology involves T-cells, white blood cells that help the immune system fight disease and infection.

Re-engineering T-cells

CAR-T therapies re-engineer the blood to recognise cancer cells that have been hiding in the body that haven’t been destroyed.

In clinical trials, Kymriah has proved effective, even in patients with the advanced form of the disease, so its rollout here in the UK will be welcomed by young leukaemia sufferers. But because it is a complex, personalised treatment the Novartis innovation is also eye-wateringly expensive with a list price of £282,000 per year.

And it isn’t exactly a silver bullet. About 400 children are diagnosed with acute lymphoblastic leukaemia each year but nly 15 might be suitable for the CAR-T treatment.

Hot area of research

Nevertheless, this area of immuno-oncology has become a popular field of research with UK companies at the forefront of the latest innovations.

Leading the pack is Autolus Therapeutics, a spin-out from University College  London, which is now listed in the US with a market capitalisation in excess of US$1bn.

Backed in its formative stages by Arix Biosciences and Neil Woodford’s Patient Capital, it is running five CAR-T programmes covering six blood-borne cancers and solid tumour indications.

Smaller, with a market cap of US$162mln, but a potential pocket rocket is AIM-listed MaxCyte (LON:MXCT), which is gearing up to begin clinical trials of MCY-M11, a chimeric antigen receptor that targets solid tumours.

The phase I study will evaluate the safety of the potential treatment in people with relapsed, or difficult-to-treat ovarian cancer and peritoneal mesothelioma (a form of cancer that affects the abdomen). MaxCyte used its CARMA platform to develop the treatment.

Unsung hero

Finally, Oxford Biomedica (LON:OXB) has been slightly overlooked in all the hullaballoo about Kymriah.

Yet without its technology, the treatment wouldn’t exist. For OXB is the sole manufacturer of the lentiviral vector that encodes the CD19-directed chimeric antigen receptor in Kymriah.

For those who didn’t understand the foregoing, a lentiviral vector is a method used to insert, modify or delete human genes.

Effectively, it re-programmes the T-cells.

]]>
Wed, 05 Sep 2018 15:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204261/car-t-therapies-all-you-wanted-to-know-and-were-too-afraid-to-ask-204261.html
<![CDATA[RNS press release - Notice of Half Year Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180903070009_13775651/ Mon, 03 Sep 2018 07:00:09 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180903070009_13775651/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180726173345_13733293/ Thu, 26 Jul 2018 17:33:45 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180726173345_13733293/ <![CDATA[News - MaxCyte gears up for first clinical trial after gaining regulatory green light ]]> https://www.proactiveinvestors.co.uk/companies/news/200817/maxcyte-gears-up-for-first-clinical-trial-after-gaining-regulatory-green-light-200817.html MaxCyte Inc (LON:MXCT) shares rose on Monday after the firm said it had received the green light to embark on its first-ever clinical trial as it told investors the commercial arm of the business was trading in line with forecasts.

The US Food & Drug Administration has given the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours.

READ: MaxCyte hails US National Institutes of Health tie-up to find treatment for sickle cell disease

The phase I clinical study will evaluate the safety of the potential treatment in people with relapsed, or difficult-to-treat ovarian cancer and peritoneal mesothelioma (a form of cancer that affects the abdomen).

MaxCyte used its CARMA platform to develop the cancer treatment. The technology incites the body’s own immune system to tackle the killer disease, which is a hot area at the moment.

New and innovative technology

What’s new and innovative, even for this very new and innovative strand of research, is that CARMA is being designed to grapple with solid tumours.

The breakthroughs in this field, such as CAR (chimeric antigen receptor) T-cell immuno-therapies, fight blood-borne illness, and yet 90% of cancers are solid tumours.

Chief executive Doug Doerfler said the regulatory sign-off marked an “important milestone” for the business.

“We are excited to advance MCY-M11, our first therapeutic candidate in solid tumours into the clinic and we hope that the upcoming study will serve as validation of our proprietary CARMA (CAR therapeutic) drug platform as a whole," he added.

MaxCyte isn’t the typical, binary, heads-you-win, tails-you-lose drug developer you find traditionally on AIM. It has a hybrid business. So, it sells and licenses its cell engineering technology to some of the world’s largest pharma and biotechnology companies.

Revenues up 27%

In the second of two announcements, MaxCyte told investors first-half revenues were US$6.9mln, up 11.6% on the year earlier and in line with market expectations.

It is partnered with commercial and academic cell therapy developers and revealed it now has more than 55 licensed programmes covering an increasingly diverse range of fields, including immuno-oncology, gene editing and regenerative medicine.

MaxCyte has increased the number of licences to partners covering clinical-stage programmes to more than 25 (up from 15 at the same point last year).

“This is a significant acceleration of the number of partners advancing towards commercialisation-stage with the goal of providing new therapies to individuals facing diseases such as triple-negative breast cancer, Hodgkins lymphoma, paediatric leukaemia and other blood cancers, HIV and sickle cell disease,” it added.

The shares were up 4% at 247.5p, valuing the business at £126mln.

 -- Adds share price --

]]>
Mon, 16 Jul 2018 07:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/200817/maxcyte-gears-up-for-first-clinical-trial-after-gaining-regulatory-green-light-200817.html
<![CDATA[RNS press release - FDA IND Clearance for First Clinical Programme ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180716070005_13718192/ Mon, 16 Jul 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180716070005_13718192/ <![CDATA[News - MaxCyte hails US National Institutes of Health tie-up to find treatment for sickle cell disease ]]> https://www.proactiveinvestors.co.uk/companies/news/198577/maxcyte-hails-us-national-institutes-of-health-tie-up-to-find-treatment-for-sickle-cell-disease-198577.html MaxCyte Inc (LON:MXCT) shares rose on Monday after it said it has entered into an R&D agreement with the US National Institutes of Health (NIH) to develop treatments for sickle cell disease. 

They will do so using next-generation CRISPR/Cas9-based single-nucleotide correction technologies enabled by MaxCyte's cell engineering platform.

The collaboration will be with National Heart, Lung and Blood Institute, which is part of the NIH.

Correcting mutations

The two hope to "correct" the faulty haemoglobin gene that causes the disease and address DNA mutations that contribute to the disease. 

As part of the tie-up, MaxCyte will supply messenger RNA molecules that convey genetic information from DNA to the ribosomes.

It will also use its Flow Electroporation Technology to develop reliable and effective processes to correct gene sequences.

MaxCyte chief executive Doug Doerfler said: "We believe that this work will further validate our platform for developing gene-editing therapies for a broad range of diseases while enabling rapid, development and commercial manufacturing of new therapies for patients where there is an extremely high unmet medical need."

In early morning trading, Maxcyte shares were up 1.6% at 249p.

-- Adds share price --

 

]]>
Mon, 11 Jun 2018 07:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/198577/maxcyte-hails-us-national-institutes-of-health-tie-up-to-find-treatment-for-sickle-cell-disease-198577.html
<![CDATA[RNS press release - MaxCyte & NIH enter CRADA for Sickle Cell Disease ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180611070004_13673686/ Mon, 11 Jun 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180611070004_13673686/ <![CDATA[News - MaxCyte pre-clinical data shows correction of sickle cell disease mutation ]]> https://www.proactiveinvestors.co.uk/companies/news/197343/maxcyte-pre-clinical-data-shows-correction-of-sickle-cell-disease-mutation-197343.html MaxCyte Inc's (LON:MXCT) technology may have a role to play in the treatment of sickle cell disease (SCD).

Pre-clinical data presented Friday (May 18) at an industry assessed the use of  non-viral CRISPR-mediated gene-correction in the treatment of the blood disorder.

The data from work with the National Institutes of Health's National Heart Lung and Blood Institute demonstrated the potential of MaxCyte's technologies and the non-viral CRISPR gene correction in the treatment of SCD.

READ: The abstract here 

Delegates at the American Society of Gene and Cell Therapy, held in Chicago, were provided the information in a poster.

The company's chief executive, Doug Doerfler, said: "We're encouraged that MaxCyte's technology is at the forefront of enabling non-viral  CRISPR-mediated correction of disease mutations at clinically-relevant levels.

"We're excited by these results for their potential to bring therapeutic benefit to individuals living with SCD."

 

]]>
Mon, 21 May 2018 07:33:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197343/maxcyte-pre-clinical-data-shows-correction-of-sickle-cell-disease-mutation-197343.html
<![CDATA[RNS press release - Preclinical Results at ASGCT Annual Meeting ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180521070012_13647895/ Mon, 21 May 2018 07:00:12 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180521070012_13647895/ <![CDATA[RNS press release - Notice of AGM and Annual Report ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180430070018_13622833/ Mon, 30 Apr 2018 07:00:18 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180430070018_13622833/ <![CDATA[News - MaxCyte appoints Infinity Pharma's Claudio Dansky Ullmann as its chief medical officer ]]> https://www.proactiveinvestors.co.uk/companies/news/195733/maxcyte-appoints-infinity-pharma-s-claudio-dansky-ullmann-as-its-chief-medical-officer-195733.html MaxCyte Inc (LON:MXCT) has announced the appointment of Claudio Dansky Ullmann as its chief medical officer, as the firm prepares for clinical testing of its first cell therapy drug candidate.

The AIM-listed company said in his new role, Ullmann will be responsible for overseeing clinical development of MaxCyte’s CARMA drug development program, with the company’s first candidate, MCY-M11, is expected to enter the clinic this year.

READ: MaxCyte reports strong growth in cash and total assets in 2017 as revenues increase by 14%

The global cell-based medicines and life sciences company said Ullmann brings more than 25 years of experience in clinical oncology and drug development.

He was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals, where he oversaw all clinical development and operations, shaped corporate strategy and was directly involved in business development activities.

He also worked at the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) and held research roles at the National Institute of Health.

Doug Doerfler, MaxCyte’s CEO, said: “His broad experience in cancer therapy drug development will be invaluable at this stage in MaxCyte’s evolution form a cell engineering technology company to a drug developer with a pipeline of CARMA drug candidate programs.”

The CEO added: “Furthermore, with his deep understanding of the development of immune-oncology therapies and other cancer treatments, Claudio will help us to advance our Flow Electroporation technology to enable our partners to make important medical.

]]>
Wed, 25 Apr 2018 09:47:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195733/maxcyte-appoints-infinity-pharma-s-claudio-dansky-ullmann-as-its-chief-medical-officer-195733.html
<![CDATA[RNS press release - CMO Appointment ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180425070012_13617312/ Wed, 25 Apr 2018 07:00:12 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180425070012_13617312/ <![CDATA[News - MaxCyte reports strong growth in cash and total assets in 2017 as revenues increase by 14% ]]> https://www.proactiveinvestors.co.uk/companies/news/194227/maxcyte-reports-strong-growth-in-cash-and-total-assets-in-2017-as-revenues-increase-by-14-194227.html MaxCyte Inc (LON:MXCT) reported strong growth in its cash and total assets in 2017 as revenues increased by 14% and gross margins remained stable.

The AIM-listed global cell-based medicines and life sciences company said its revenue for the year to 31 December 2017 was US$14.0mln, up from US$12.3mln a year earlier, with gross margins unchanged at 90%.

READ: MaxCyte prepares for phase I study of potential cancer breakthrough

The firm is developing CARMA, an mRNA-based proprietary chimeric antigen receptor (CAR) platform for autologous cell therapy.

MaxCyte said its investment in CARMA in 2017 was US$7.5mln, up from US$1.3mln in 2016 as the company prepared and completed the filing of its first investigational new drug application with the US Food & Drug Administration.

The group’s net loss before​ CARMA investment was US$2.4mln in 2017, up from a US$2.0mln net loss in 2016, while adjusted underlying earnings (EBITDA) before CARMA investment was a loss of US$1.2mln in both 2016 and 2017.

As at 31 December 2017, MaxCyte’s total assets were US$31.4mln, up from US$16.1mln a year earlier, with its cash and cash equivalents totalling US$25.3mln, up from $11.7mln in 2016, boosted by its successful fund raise of US$25.5mln in April 2017.

Core markets growing very rapidly

Commenting on the annual results, Doug Doerfler, MaxCyte’s CEO said: "Our core markets, cell therapy and immuno-oncology, are growing very rapidly.

“With our unique technology, we remain at the forefront of a wide variety of programmes across this exciting and increasingly valuable area of healthcare.”

He added: “This is a very exciting time for the Company and patients as we bring a new generation of CAR-based cancer treatments into the clinic for the first time, and continue to enable our partners to make important new medical advancements.

“We look forward to the future with great confidence."  

]]>
Wed, 04 Apr 2018 08:19:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/194227/maxcyte-reports-strong-growth-in-cash-and-total-assets-in-2017-as-revenues-increase-by-14-194227.html
<![CDATA[RNS press release - Final Results for Year Ended 31 December 2017 ]]> https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180404070003_13590509/ Wed, 04 Apr 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14537/LSE20180404070003_13590509/